Dr. Pamela Kunz on the Effectiveness of Immunotherapies and Their Promising Future
November 3rd 2015Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.